JP5794693B2 - 神経分化促進剤 - Google Patents
神経分化促進剤 Download PDFInfo
- Publication number
- JP5794693B2 JP5794693B2 JP2011506509A JP2011506509A JP5794693B2 JP 5794693 B2 JP5794693 B2 JP 5794693B2 JP 2011506509 A JP2011506509 A JP 2011506509A JP 2011506509 A JP2011506509 A JP 2011506509A JP 5794693 B2 JP5794693 B2 JP 5794693B2
- Authority
- JP
- Japan
- Prior art keywords
- coup
- protein
- cells
- neural
- neurons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000004031 neuronal differentiation Effects 0.000 title claims description 10
- 210000002569 neuron Anatomy 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 71
- 210000001178 neural stem cell Anatomy 0.000 claims description 61
- 210000005155 neural progenitor cell Anatomy 0.000 claims description 53
- 230000004069 differentiation Effects 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 102000013014 COUP Transcription Factor I Human genes 0.000 claims description 35
- 108010065376 COUP Transcription Factor I Proteins 0.000 claims description 35
- 102000008523 COUP Transcription Factor II Human genes 0.000 claims description 32
- 108010020650 COUP Transcription Factor II Proteins 0.000 claims description 32
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 28
- 239000004055 small Interfering RNA Substances 0.000 claims description 26
- 230000001537 neural effect Effects 0.000 claims description 19
- 230000004568 DNA-binding Effects 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 claims description 15
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 14
- 210000001222 gaba-ergic neuron Anatomy 0.000 claims description 13
- 210000002932 cholinergic neuron Anatomy 0.000 claims description 12
- 102000012749 Dopamine and cAMP-Regulated Phosphoprotein 32 Human genes 0.000 claims description 9
- 108010090047 Dopamine and cAMP-Regulated Phosphoprotein 32 Proteins 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 210000001362 glutamatergic neuron Anatomy 0.000 claims description 8
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 108020004459 Small interfering RNA Proteins 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 102000004101 COUP Transcription Factors Human genes 0.000 description 33
- 108010043071 COUP Transcription Factors Proteins 0.000 description 33
- 238000000034 method Methods 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000006957 competitive inhibition Effects 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 210000000130 stem cell Anatomy 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000004853 protein function Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000004720 fertilization Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 241000713666 Lentivirus Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 210000001130 astrocyte Anatomy 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000002161 motor neuron Anatomy 0.000 description 6
- 210000004498 neuroglial cell Anatomy 0.000 description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 108700007229 noggin Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000003693 Hedgehog Proteins Human genes 0.000 description 4
- 108090000031 Hedgehog Proteins Proteins 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 102000045246 noggin Human genes 0.000 description 4
- 210000004248 oligodendroglia Anatomy 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 239000005700 Putrescine Substances 0.000 description 3
- 102000004338 Transferrin Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- VIEXQFHKRAHTQS-UHFFFAOYSA-N chloroselanyl selenohypochlorite Chemical compound Cl[Se][Se]Cl VIEXQFHKRAHTQS-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 239000012581 transferrin Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 102100032491 Serine protease 1 Human genes 0.000 description 2
- 101710151387 Serine protease 1 Proteins 0.000 description 2
- 101710119665 Trypsin-1 Proteins 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000037426 transcriptional repression Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 1
- -1 Bicoid Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108700026311 Drosophila En Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 101000616468 Mus musculus Sonic hedgehog protein Proteins 0.000 description 1
- 108091008747 NR2F3 Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 101150027852 pou3f2 gene Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 101150077014 sox10 gene Proteins 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Insects & Arthropods (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
Description
本出願は、2008年8月13日に出願された米国仮出願61/088,521を基礎とする優先権の利益を主張するものであって、当該基礎出願を援用する。
本発明にかかる薬剤は、神経幹細胞/神経前駆細胞の神経分化を促進するために用いられ、COUP-TFIタンパク質及び/又はCOUP-TFIIタンパク質の機能を抑制する機能抑制物質を含有する。本明細書では、神経幹細胞/神経前駆細胞の神経分化を促進するとは、神経分化促進剤を投与することによって神経幹細胞/神経前駆細胞が分化するとき、グリアの割合が減少し、ニューロンの割合が増加するようになることをいう。なお、その神経幹細胞/神経前駆細胞は、in vivoに存在する細胞でも、in vitroにある細胞でも構わない。
COUP-TFタンパク質(本明細書では、遺伝子の場合であってもタンパク質の場合であっても、Coup-tfI及びCoup-tfIIを総称してCoup-tfと称するものとする。)の由来は、ヒトやマウスのような脊椎動物由来であればよく、対象とする神経幹細胞/神経前駆細胞の由来と同じであることが好ましいが、それらの由来が違っていても、COUP-TFタンパク質の機能を抑制する機能抑制物質が、目的とする細胞の有するCOUP-TFタンパク質の機能を抑制するものであればよい。
COUP-TFタンパク質の機能抑制物質は、当業者に周知の薬学的に許容される担体、希釈剤、腑形剤等の製剤用添加物を用いて剤形化し、神経分化促進剤とすることができる。この薬剤は、in vitroでの実験用試薬としても、in vivoでの医薬としても使用できる。
本実施例では、神経幹細胞/神経前駆細胞においてCoup-tf遺伝子をノックダウンすると、この細胞を分化状態においた時、ニューロンへ優先的に分化するようになることが記載される。
EB3細胞は、未分化ES細胞を選択できるように、129/Ola系マウス由来のES細胞系列E14tg2aのOct3/4遺伝子座にブラストシジン耐性遺伝子を挿入して得られたものである。そのEB3細胞を、10%FCS、非必須アミノ酸、1mMピルビン酸ナトリウム、0.1mM 2−メルカプトエタノール及び1000U/mL白血病抑制因子(LIF)を含むGlasgow minimum essential medium(GMEM)を用いて、5%CO2、37℃の条件で培養した。
このようにして形成したEBに対し、0.25%トリプシン−1mM EDTA溶液で処理して、細胞を分散させた。分散させた細胞はグルコース(0.6%)、グルタミン(2mM)、インスリン(25μg/mL)、トランスフェリン(100μg/mL)、プロジェステロン(20nM)、プトレシン(60μM)、塩化セレン(30nM)、FGF−2(20ng/mL)、ヘパリン(2μg/mL)を添加したDMEM:F12(1:1)に、さらにマウスソニックヘッジホッグタンパク質(mouse sonic hedgehog1)(5nM)を加えたMHM培地を用い、バクテリア用培養皿中に5x104個/mLの濃度で播種し、7〜9日間浮遊培養することによって、一次ニューロスフェアを形成させた。
Coup-tfI遺伝子及びCoup-tfII遺伝子のノックダウンのためのshRNAの配列は、オンラインsiRNAデザインプログラムsiDirect(http://design.mai.jp/)を用いて設計した(それぞれ、Coup-tfI KD 及びCoup-tfII KDと称する)。ネガティブコントロールとして、pSilencer 2.1-U6 Negative Control(Ambion社)及びCoup-tfI KD 及びCoup-tfII KDにおいて、1塩基、2塩基または3塩基置換された変異体を用いた。これらの配列は以下の通りである。
KDI(Coup-tfI KD用):GATGCTGCCCACATCGAAATTCAAGAGATTTCGATGTGGGCAGCATC(配列番号3)
KDII(Coup-tfII KD用):GTCCCAGTGTGCTTTGGAATTCAAGAGATTGGAAAGCACACTGGGAC(配列番号4)
KDI+II(Coup-tf KD用):GTCGAGCGGCAAGCACTACTTCAAGAGAGTAGTGCTTGCCGCTCGAC(配列番号5)
2.1-U6:ACTACCGTTGTTATAGGTGTTCAAGAGACACCTATAACAACGGTAGT(配列番号6)
shRNAが導入されたニューロスフェアの継代ごとに、一部の前記ニューロスフェアを、ピペッティングにより分散し、分化培地で満たしたポリ−L−オルニチン(poly-L-ornithin)でコートした培養皿に播種し、ソニックヘッジホッグタンパク質(5nM)存在下で5〜7日間培養することによって分化させた。その後、その細胞を、ニューロンのマーカーとして使用される抗βIIIチューブリン抗体(マウスIgG、Sigma社 T8660、1000分の1希釈)、アストロサイトのマーカーとして使用される抗GFAP抗体(ウサギIgG、DAKO社 Z0334、400分の1希釈)、オリゴデンドロサイトのマーカーとして使用される抗O4抗体(マウスIgM、Chemicon社 MAB345、8000分の1希釈)で免疫染色し、蛍光顕微鏡を用いて、細胞形態と染色された細胞タイプを観察した(図2)。各サンプルで、ニューロン、アストロサイト、オリゴデンドロサイトの細胞数を数え、各細胞種の割合をグラフにプロットした(図3)。
本実施例では、マウス生体内における神経幹細胞/神経前駆細胞の分化において、Coup-tf遺伝子のノックダウンが、神経分化を促進することを示す。
本実施例では、妊娠10.5日目あるいは12.5日目のICRマウスの子宮内で、マウス胚の大脳脳室に、実施例1に記載のshRNA含有レンチウイルスを微小注入した。10.5日目の微小注入では、VS40及びVevo660(VisualSonics社)を利用した。
受精後10.5日にshRNA含有レンチウイルスを感染させたマウスの脳については16.5日胚の段階(図5)で、また、受精後12.5日に感染させたマウスの脳については生後20日目の段階(図6)で、免疫組織化学的解析を行った。
in vivoでCOUP-TFを阻害することによって分化させたニューロンの細胞タイプを決めるため、受精後10.5日にshRNA含有レンチウイルスを感染させたマウスの脳について、受精後16.5日胚の段階で、抗Isl-1抗体、抗DARPP-32抗体(Chemicon社 2000分の1希釈)、抗Tbr1抗体(R.F.Hevner博士(ワシントン大学)より供与 10000分の1希釈)、または抗Brn-2抗体(Santa Cruz Biotechnology社 500分の1希釈)を用いて、免疫組織化学的解析を行った(図7)。受精後15.5日に生まれた細胞を、BrdUの取り込みによって標識し、切片を1N HClで室温30分処理してDNAを変性させて前処理した後、抗BrdU抗体(Abcam社 100分の1希釈)を用いて、BrdUに対する免疫組織化学染色を行った。用いたネガティブコントロールは、(2)で用いたものと同一である。
本実施例では、神経幹細胞/神経前駆細胞において、COUP-TFタンパク質のDNA結合機能を競合阻害することにより、神経分化を促進できることを示す。
本実施例で用いる融合タンパク質として、COUP-TFIタンパク質のN末端にあるDNA結合ドメイン(配列番号1において、2−403番目のアミノ酸配列)またはCOUP-TFIIタンパク質のN末端にあるDNA結合ドメイン(配列番号2において、2−394番目のアミノ酸配列)を、VP16の転写活性化ドメイン(配列番号7 <P06492> において、413−490番目のアミノ酸配列)またはDrosophilaのEngrailed(En)タンパク質の転写抑制ドメイン(配列番号8 <NM 078976> において、2−295番目のアミノ酸配列)と結合させて、ドミナント・ポジティブ変異体(以下、VP-1またはVP-IIと称する)またはドミナント・ネガティブ変異体(以下、EnIまたはEnIIと称する)を作製し、それぞれを混合して用いた(混合したタンパク質を、それぞれVP-I/II及びEnI/IIと称する)。これらの融合タンパク質は、COUP-TFタンパク質のN末端にある転写調節領域を有しない。コントロールとしては、COUP-TFI/II(野生型COUP-TFIと野生型COUP-TFIIを混合したもの)及びF-I/II(N末端にflag-tag(DYKDDDDK: 配列番号9)を結合させた野生型COUP-TFIと野生型COUP-TFIIを混合したもの)を用いた。すなわち、VP-1、VP-II、EnI及びEnIIについては、Met-FLAG-GlySer-VP/En-LysLeuArgSer-COUP、F-I及びF-IIについては、Met-FLAG-GlySer-COUPという構造を有する(ただし、VP/ENは、VP-1、VP-II、EnI及びEnIIのいずれかを表し、COUPは、COUP-TFIまたはCOUP-TFIIのDNA結合ドメインを表す。)。これらの融合タンパク質の構造の模式図を図8に示す。
実施例1と同様に、ES細胞由来の神経幹細胞/神経前駆細胞を用い、一次ニューロスフェアに、融合タンパク質をコードする組換え遺伝子を有するレンチウイルスを感染させ、継代3代目に細胞を分化させて、全細胞に対するニューロンの割合を算出した。図9に示すように、その結果をグラフ化した。
Claims (6)
- 胚性幹細胞または多能性幹細胞に由来するか、または生体内に存在する神経幹細胞/神経前駆細胞をコリン作動性ニューロン、GABA作動性ニューロン又はグルタミン酸作動性ニューロンへ分化誘導するための神経分化促進剤であって、
COUP-TFIタンパク質及び/又はCOUP-TFIIタンパク質をコードする遺伝子の発現を抑制する核酸分子である発現抑制剤を含有することを特徴とする神経分化促進剤。 - 前記核酸分子がshRNAまたはsiRNAであることを特徴とする請求項1に記載の神経分化促進剤。
- 胚性幹細胞または多能性幹細胞に由来するか、または生体内に存在する神経幹細胞/神経前駆細胞をコリン作動性ニューロン、GABA作動性ニューロン又はグルタミン酸作動性ニューロンへ分化誘導するための神経分化促進剤であって、
転写活性化ドメインと、COUP-TFIタンパク質及び/又はCOUP-TFIIタンパク質のDNA結合ドメインと、を有するCOUP-TFIタンパク質及び/又はCOUP-TFIIタンパク質の変異体を含有することを特徴とする神経分化促進剤。 - 前記神経幹細胞/神経前駆細胞が、一次ニューロスフェアであることを特徴とする請求項1〜3のいずれか1項に記載の神経分化促進剤。
- 分化したニューロンが、Isl-1陽性ニューロン、DARPP-32陽性ニューロン、またはTbr-1陽性ニューロンであることを特徴とする請求項1〜4のいずれか1項に記載の神経分化促進剤。
- 外傷性脳障害、ハンチントン病、またはアルツハイマー病の治療薬であって、以下のいずれかを有効成分として含有する治療薬。
(1)COUP-TFIタンパク質またはCOUP-TFIIタンパク質をコードする遺伝子の発現を抑制する核酸分子である発現抑制剤
(2)転写活性化ドメインと、COUP-TFIタンパク質またはCOUP-TFIIタンパク質のDNA結合ドメインと、を有するCOUP-TFIタンパク質またはCOUP-TFIIタンパク質の変異体
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8852108P | 2008-08-13 | 2008-08-13 | |
US61/088,521 | 2008-08-13 | ||
PCT/JP2009/003195 WO2010018652A1 (en) | 2008-08-13 | 2009-07-08 | Agent for promoting neuronal differentiation and method therefor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011530484A JP2011530484A (ja) | 2011-12-22 |
JP2011530484A5 JP2011530484A5 (ja) | 2012-08-23 |
JP5794693B2 true JP5794693B2 (ja) | 2015-10-14 |
Family
ID=41668806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011506509A Expired - Fee Related JP5794693B2 (ja) | 2008-08-13 | 2009-07-08 | 神経分化促進剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110183912A1 (ja) |
EP (1) | EP2326333B1 (ja) |
JP (1) | JP5794693B2 (ja) |
AU (1) | AU2009280769B2 (ja) |
CA (1) | CA2733775A1 (ja) |
WO (1) | WO2010018652A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012112737A2 (en) * | 2011-02-16 | 2012-08-23 | The Regents Of The University Of California | Alzheimer's disease cellular model for diagnostic and therapeutic development |
WO2013162027A1 (ja) * | 2012-04-27 | 2013-10-31 | 学校法人 慶應義塾 | 神経分化促進剤 |
US11332719B2 (en) * | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
WO2019222134A1 (en) * | 2018-05-14 | 2019-11-21 | Baylor College Of Medicine | Coup-tfii receptor inhibitors and methods using same |
US20230377685A1 (en) | 2022-04-15 | 2023-11-23 | Aspen Neuroscience, Inc. | Methods of classifying the differentiation state of cells and related compositions of differentiated cells |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8760298A (en) * | 1997-08-01 | 1999-02-22 | Baylor College Of Medicine | Coup-tfi directed therapies in the treatment of disease |
US6395546B1 (en) * | 2000-02-01 | 2002-05-28 | Neurogeneration, Inc. | Generation of dopaminergic neurons from human nervous system stem cells |
JP3660601B2 (ja) * | 2001-03-30 | 2005-06-15 | 独立行政法人科学技術振興機構 | 胚性幹細胞からの神経幹細胞、運動ニューロン及びgaba作動性ニューロンの製造法 |
EP1456374A4 (en) * | 2001-11-26 | 2005-08-17 | Advanced Cell Tech Inc | METHODS FOR THE PRODUCTION AND USE OF REPROGRAMME HUMAN SOMATIC CELL CORES AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS |
WO2005017112A2 (en) * | 2003-08-05 | 2005-02-24 | Immusol Incorporated | Methods of inhibiting cancer growth by binding to nuclear receptors |
US20070184459A1 (en) * | 2006-02-03 | 2007-08-09 | Immusol Incorporated | Methods of inhibiting cancer growth by binding to nuclear receptors |
-
2009
- 2009-07-08 EP EP09806548.5A patent/EP2326333B1/en not_active Not-in-force
- 2009-07-08 JP JP2011506509A patent/JP5794693B2/ja not_active Expired - Fee Related
- 2009-07-08 CA CA2733775A patent/CA2733775A1/en not_active Abandoned
- 2009-07-08 US US13/058,621 patent/US20110183912A1/en not_active Abandoned
- 2009-07-08 AU AU2009280769A patent/AU2009280769B2/en not_active Ceased
- 2009-07-08 WO PCT/JP2009/003195 patent/WO2010018652A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2009280769B2 (en) | 2014-09-18 |
US20110183912A1 (en) | 2011-07-28 |
AU2009280769A2 (en) | 2011-03-31 |
AU2009280769A1 (en) | 2010-02-18 |
CA2733775A1 (en) | 2010-02-18 |
JP2011530484A (ja) | 2011-12-22 |
EP2326333A4 (en) | 2013-01-23 |
WO2010018652A1 (en) | 2010-02-18 |
EP2326333A1 (en) | 2011-06-01 |
EP2326333B1 (en) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | NG2 glia regulate brain innate immunity via TGF-β2/TGFBR2 axis | |
US11167044B2 (en) | Regenerating functional neurons for treatment of disease in the nervous system | |
Yu et al. | MSX3 switches microglia polarization and protects from inflammation-induced demyelination | |
Liu et al. | miR‐219 attenuates demyelination in cuprizone‐induced demyelinated mice by regulating monocarboxylate transporter 1 | |
JP6316938B2 (ja) | Hmga2を用いて非神経細胞からリプログラミングされた誘導神経幹細胞を調製する方法 | |
US20150299698A1 (en) | Methods for engineering non-neuronal cells into neurons and using newly engineered neurons to treat neurodegenerative diseases | |
JP2021520200A (ja) | 非神経細胞のニューロンへの再プログラミング、及び神経変性疾患または障害を治療するための方法と組成物 | |
Yan et al. | Neurotrophin-3 promotes proliferation and cholinergic neuronal differentiation of bone marrow-derived neural stem cells via notch signaling pathway | |
JP5794693B2 (ja) | 神経分化促進剤 | |
US20160289676A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING NF- kB AND SOD-1 TO TREAT AMYOTROPHIC LATERAL SCLEROSIS | |
Zhou et al. | Retroviral lineage analysis of fibroblast growth factor receptor signaling in FGF2 inhibition of oligodendrocyte progenitor differentiation | |
Prozorovski et al. | Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells | |
Zhou et al. | Targeting RPTPσ with lentiviral shRNA promotes neurites outgrowth of cortical neurons and improves functional recovery in a rat spinal cord contusion model | |
Morell et al. | Inducible expression of noggin selectively expands neural progenitors in the adult SVZ | |
Wang et al. | Function of B-Cell CLL/Lymphoma 11B in glial progenitor proliferation and oligodendrocyte maturation | |
Zhan et al. | A DEAD‐box RNA helicase Ddx54 protein in oligodendrocytes is indispensable for myelination in the central nervous system | |
Gu et al. | Sprouty1 regulates neuritogenesis and survival of cortical neurons | |
Fujimoto et al. | RBP-J promotes neuronal differentiation and inhibits oligodendroglial development in adult neurogenesis | |
US20210228741A1 (en) | Methods and compositions to stimulate retinal regeneration | |
WO2020227213A1 (en) | Methods of controlling and improving brain health | |
Zahir et al. | Sorbitol causes preferential selection of Muller glial precursors from late retinal progenitor cells in vitro | |
KR102594254B1 (ko) | 운동성 신경세포 직접교차 분화용 인자 | |
WO2022186089A1 (ja) | 神経変性疾患治療のためのポリヌクレオチド、ベクター、細胞、医薬組成物及びスクリーニング方法 | |
JP6194517B2 (ja) | 神経分化促進剤 | |
Jing et al. | miR-26a promotes axon regeneration in the mammalian central nervous system by suppressing PTEN expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120706 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131001 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140805 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141003 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150317 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150617 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150701 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150721 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150807 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5794693 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |